© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
August 11, 2022
Oncologists share some final thoughts on lutetium-PSMA-617 and novel agents to look out for in prostate cancer treatment.
July 29, 2022
Alicia Morgans, MD, MPH, presents the case of a 67-year-old man with metastatic castration-resistant prostate cancer.
Experts share their thoughts on sequencing hormonal agents and patient selection for clinical trials.
July 26, 2022
A review of recent data from the TheraP trial.
Tanya Dorff, MD, explains safety and efficacy data from the CARD trial.
July 18, 2022
Dr Tanya Dorff presents the case of a 72-year-old man with metastatic hormone-sensitive prostate cancer.